Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a well-known side effect of certain drugs that are used to influence bone metabolism to treat osteometabolic disease or cancers. The purpose of our study was to investigate how high-concentration and low-concentration bisphosphonate (BP) intake affects the disease severity. Materials and Methods: Data collected from the medical records of 52 patients treated with BPs, antiresorptive, antiangiogenic drugs and diagnosed with MRONJ were included in this study. Age, sex, type of systemic disease, type of drug, duration of drug treatment, jaw area with MRONJ, drug administration protocol, and MRONJ clinical and radiological findings were obtained. Patients were divided into two groups: anti-neoplastic (Group I, n=23) and anti-osteoporotic (Group II, n=29). Statistical evaluations were performed using the IBM SPSS ver. 21.0 program. Results: In both groups, more females had MRONJ. MRONJ was found in the mandibles of 30 patients (Group I, n=14; Group II, n=16). When we classified patients according to the American Association of Oral and Maxillofacial Surgeons staging system, significant differences were seen between groups (χ2=12.23, P<0.01). More patients with advanced stage (stage 2-3) MRONJ were found in Group I (60.9%). Conclusion: According to our results, high-concentration BP intake, age and duration of drug intake increased disease severity.
Abstract
Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is a well-known side effect of certain drugs that are used to influence bone metabolism to treat osteometabolic disease or cancers. The purpose of our study was to investigate how high-concentration and low-concentration bisphosphonate (BP) intake affects the disease severity. Materials and Methods: Data collected from the medical records of 52 patients treated with BPs, antiresorptive, antiangiogenic drugs and diagnosed with MRONJ were included in this study. Age, sex, type of systemic disease, type of drug, duration of drug treatment, jaw area with MRONJ, drug administration protocol, and MRONJ clinical and radiological findings were obtained. Patients were divided into two groups: anti-neoplastic (Group I, n=23) and anti-osteoporotic (Group II, n=29). Statistical evaluations were performed using the IBM SPSS ver. 21.0 program. Results: In both groups, more females had MRONJ. MRONJ was found in the mandibles of 30 patients (Group I, n=14; Group II, n=16). When we classified patients according to the American Association of Oral and Maxillofacial Surgeons staging system, significant differences were seen between groups (χ2=12.23, P<0.01). More patients with advanced stage (stage 2-3) MRONJ were found in Group I (60.9%). Conclusion: According to our results, high-concentration BP intake, age and duration of drug intake increased disease severity.
참고문헌 (25)
- Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
- Rosen LS, "Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : a randomized, Phase III, double-blind, placebo-controlled trial", Cancer, 100, pp.2613~2621 (2004)
- Benhamou CL, "Effects of osteoporosis medications on bone quality", Joint Bone Spine, 74, pp.39~47 (2007)
- review : bisphosphonates and osteonecrosis of the jaws, "Ann Intern Med", 2006, 753~761
- Ruggiero S, "Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer", J Oncol Pract, 2, pp.7~14 (2006)
- Hokugo A, "Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats", J Bone Miner Res, 25, pp.1337~1349 (2010)
- Ruggiero SL, "Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw -2009 update", Aust Endod J, 35, pp.119~130 (2009)
- Campisi G, "Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis", Ann Oncol, 18(Suppl 6), pp.vi168~vi172 (2007)
- Tae-Hwan Kim, "Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies", 대한구강악안면외과학회지, 42(4), pp.193~204 (2016), 대한구강악안면외과학회
- Ruggiero SL, "Bisphosphonate-related osteonecrosis of the jaw : background and guidelines for diagnosis, staging and management", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, pp.433~441 (2006)
- Zervas K, "Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma : a single-centre experience in 303 patients", Br J Haematol, 134, pp.620~623 (2006)
- Pazianas M, "A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates : prevalence, risk factors, and clinical characteristics", Clin Ther, 29, pp.1548~1558 (2007)
- Lo JC, "Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure", J Oral Maxillofac Surg, 68, pp.243~253 (2010)
- Berenson JR, "Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid", Am J Hematol, 86, pp.25~30 (2011)
- Dimopoulos MA, "Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates : evidence of increased risk after treatment with zoledronic acid", Haematologica, 91, pp.968~971 (2006)
- Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)
- Marx RE, "Bisphosphonateinduced exposed bone(osteonecrosis", osteopetrosis)of the jaws : risk factors, recognition, prevention, and treatment, 2005, pp.63, 1567~1575
- Badros A, "Osteonecrosis of the jaw in multiple myeloma patients : clinical features and risk factors", J Clin Oncol, 24, pp.945~952 (2006)
- Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27, pp.5356~5362 (2009)
- Henry DH, "Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer)or multiple myeloma", J Clin Oncol, 29, pp.1125~1132 (2011)
- Yamazaki T, "Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates : a cohort study", Int J Oral Maxillofac Surg, 41, pp.1397~1403 (2012)
- Bagan JV, "Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases", Oral Oncol, 42, pp.327~329 (2006)
- Fedele S, "Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw : a case series", Am J Med, 123, pp.1060~1064 (2010)
- Hoff AO, "Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates", J Bone Miner Res, 23, pp.826~836 (2008)